Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Allergy and Immunology Clear all
Completed No phase listed Observational

HLA-B*5701 And Hypersensitivity To Abacavir

NCT00373945
View directory record Official record
Conditions
HIV Infection
Interventions
Observational Study
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
55
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 18, 2009 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 4 Interventional

A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions

NCT03576469
View directory record Official record
Conditions
CVI - Common Variable Immunodeficiency
Interventions
C1-esterase inhibitor [recombinant] (C1-INH-R)
Biological
Lead sponsor
IMMUNOe Research Centers
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Centennial, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 3 Interventional Results available

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

NCT05819775
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
CSL312
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
2 Years to 11 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Litchfield Park, Arizona • Scottsdale, Arizona • Orange, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase

NCT01426763
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
CINRYZE with rHuPH20
Biological
Lead sponsor
Shire
Industry
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Scottsdale, Arizona • Walnut Creek, California • Atlanta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

NCT01912456
View directory record Official record
Conditions
Hereditary Angioedema Types I and II
Interventions
Low-volume C1-esterase inhibitor, Higher-volume C1-esterase inhibitor, Low-volume placebo, Higher-volume placebo
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bell Gardens, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 4 Interventional

The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction

NCT06012448
View directory record Official record
Conditions
Dermal Hypersensitivity Reaction
Interventions
Dupilumab
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 1 Interventional Results available

A Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Participants

NCT02093923
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
DX-2930, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
San Diego, California • Walnut Creek, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE

NCT03485911
View directory record Official record
Conditions
Hereditary Angioedema, HAE
Interventions
BCX7353 capsules, Placebo oral capsule
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers

NCT02045264
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
Icatibant (30 mg)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 2Phase 3 Interventional Results available

12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks

NCT02303626
View directory record Official record
Conditions
Hereditary Angioedema, HAE
Interventions
BCX4161, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Granada Hills, California + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 5, 2026, 6:20 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
navenibart, Placebo
Drug
Lead sponsor
Astria Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

NCT04991935
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
CC-93538
Drug
Lead sponsor
Celgene
Industry
Eligibility
12 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 5, 2026, 6:20 PM EDT
Recruiting Phase 3 Interventional

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

NCT06960213
View directory record Official record
Conditions
Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
Interventions
ADX-324, Placebo
Drug
Lead sponsor
ADARx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Litchfield Park, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 1 Interventional

Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies

NCT01529437
View directory record Official record
Conditions
Allergies, Allergic Rhinitis, Asthma
Interventions
sublingual immunotherapy, placebo sublingual immunotherapy
Drug
Lead sponsor
Stanford University
Other
Eligibility
5 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2015 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Not applicable Interventional Results available

Metabolic Effects of Switching Kaletra to Boosted Reyataz

NCT00413153
View directory record Official record
Conditions
HIV Infections
Interventions
atazanavir/ritonavir, lopinavir/ritonavir
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 9, 2010 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Not applicable Interventional Results available

Evaluating Long Acting Beta Agonists Used to Treat Asthma Among Those With Either Arg/Arg or Gly/Gly Genotypes

NCT00521222
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone with salmeterol, Fluticasone HFA, Ipratropium HFA, Albuterol HFA
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
3
States / cities
Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 4 Interventional

Treatment of Hereditary Angioedema Prodrome with Recombinant C1-esterase Inhibitor (Ruconest)

NCT06690047
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
Ruconest
Biological
Lead sponsor
Bernstein Clinical Research Center
Other
Eligibility
14 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Birmingham, Alabama • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 5, 2026, 6:20 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

NCT05121376
View directory record Official record
Conditions
Hereditary Angioedema, HAE
Interventions
Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331, Dose 4 of BMN 331, Dose 5 of BMN 331, Dose 6 of BMN 331, Dose 7 of BMN 331
Genetic
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 5, 2026, 6:20 PM EDT
Completed No phase listed Observational

Study of Patients With Strongyloides Stercoralis Infection

NCT00001245
View directory record Official record
Conditions
HIV Infection, Nematode Infection, Strongyloidiasis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 80 Years
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1989
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2009 · Synced Oct 5, 2026, 6:20 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Angioedema Biomarker Research Study

NCT06210698
View directory record Official record
Conditions
Angioedema, Angioedemas, Hereditary, Urticaria, Mastocytosis, ACE Inhibitor-Induced Angioedema, C1 Inhibitor Deficiency, Systemic Mastocytoses, Indolent Systemic Mastocytosis
Interventions
Venipuncture
Diagnostic Test
Lead sponsor
Foundation For Rare Disease Research
Other
Eligibility
12 Years to 75 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Wheaton, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 5, 2026, 6:20 PM EDT
Withdrawn No phase listed Observational

A Study of Patients Who Recently Have Been Infected With HIV

NCT00006415
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Horsham, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 5, 2026, 6:20 PM EDT
Recruiting Phase 2 Interventional

Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor (IMPROVE TRIAL)

NCT06919003
View directory record Official record
Conditions
Kidney Transplant
Interventions
Berinert, Placebo for Berinert
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 5, 2026, 6:20 PM EDT
Completed No phase listed Observational

Clinical Sensitivity of Clearview Rapid Tests in 12-17 y/o Pediatric Population

NCT00567749
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
Chembio Diagnostic Systems, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2008 · Synced Oct 5, 2026, 6:20 PM EDT
Completed Phase 4 Interventional Results available

Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

NCT01285050
View directory record Official record
Conditions
HIV Infection, Hepatitis C
Interventions
Antiretroviral therapy (ART), raltegravir, Emtricitabine and tenofovir disoproxil fumarate
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 99 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 5, 2026, 6:20 PM EDT